Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham tells Proactive’s Elisha Newell that the company has secured ethics approval to expand its Phase 1 and 2 UTI studies with lead product RECCE® 327. The key approval will expand the number of recruits that can participate across world class trial facilities in New South Wales. Graham says R327 will be administered in around 16 participants as a broad-spectrum anti-infective, with a Phase 2 trial expected to kick off later this year.
Recce Pharmaceuticals lands ethics approval for expanded UTI studies
